Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 13Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Dwarfism, Pituitary 1Bone Diseases, Metabolic 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Risedronic Acid × Clear all
NCT00216060 2016-05-26

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Hoosier Cancer Research Network

Phase 3 Terminated
63 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

NCT00145704 2013-04-08

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

State University of New York - Upstate Medical University

Phase NA Terminated
6 enrolled 3 charts
Endocrine

Bone Diseases, Metabolic, Dwarfism, Pituitary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡